{"id":"https://openalex.org/W2407547357","doi":null,"title":"[Pharmacokinetics of epirubicin in cancer patients].","display_name":"[Pharmacokinetics of epirubicin in cancer patients].","publication_year":1986,"publication_date":"1986-05-01","ids":{"openalex":"https://openalex.org/W2407547357","mag":"2407547357","pmid":"https://pubmed.ncbi.nlm.nih.gov/3458430"},"language":"ja","primary_location":{"id":"pmid:3458430","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/3458430","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gan to kagaku ryoho. Cancer & chemotherapy","raw_type":"English Abstract"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"T Ohno","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T Ohno","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"T Shimoyama","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T Shimoyama","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028216535","display_name":"Kosei Kimura","orcid":"https://orcid.org/0000-0002-0951-5890","observed_orcids":["https://orcid.org/0000-0002-0951-5890"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K Kimura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5102808264","display_name":"Hirofumi Yamada","orcid":"https://orcid.org/0000-0002-7233-6940","observed_orcids":["https://orcid.org/0000-0002-7233-6940"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H Yamada","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"13","issue":"5","first_page":"1881","last_page":"6"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.625,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.625,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.3093000054359436,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.013399999588727951,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/epirubicin","display_name":"epirubicin","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9359999895095825},{"id":"https://openalex.org/keywords/plasma-drug-concentration","display_name":"plasma drug concentration","score":0.47600001096725464},{"id":"https://openalex.org/keywords/elimination-half-life","display_name":"elimination half-life","score":0.6869999766349792},{"id":"https://openalex.org/keywords/volume-of-distribution","display_name":"volume of distribution","score":0.7670000195503235},{"id":"https://openalex.org/keywords/area-under-the-curve","display_name":"area under the curve","score":0.7639999985694885},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.7300000190734863},{"id":"https://openalex.org/keywords/doxorubicin-comparison","display_name":"doxorubicin comparison","score":0.8730000257492065},{"id":"https://openalex.org/keywords/anthracyclines","display_name":"anthracyclines","score":0.7300000190734863},{"id":"https://openalex.org/keywords/cancer-chemotherapy","display_name":"cancer chemotherapy","score":0.6600000262260437}],"concepts":[{"id":"https://openalex.org/C2780835546","wikidata":"https://www.wikidata.org/wiki/Q425122","display_name":"Epirubicin","level":4,"score":0.9729100465774536},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8662428259849548},{"id":"https://openalex.org/C139254425","wikidata":"https://www.wikidata.org/wiki/Q1332167","display_name":"Volume of distribution","level":3,"score":0.6036738157272339},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.5369638204574585},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.533319354057312},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.5110746622085571},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5013265609741211},{"id":"https://openalex.org/C110121322","wikidata":"https://www.wikidata.org/wiki/Q865811","display_name":"Distribution (mathematics)","level":2,"score":0.4784557819366455},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4429049789905548},{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.44055435061454773},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.4331572949886322},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.390033096075058},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.36951661109924316},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3395245373249054},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.12945643067359924},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D002851","descriptor_name":"Chromatography, High Pressure Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007263","descriptor_name":"Infusions, Parenteral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007700","descriptor_name":"Kinetics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D015251","descriptor_name":"Epirubicin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:3458430","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/3458430","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gan to kagaku ryoho. Cancer & chemotherapy","raw_type":"English Abstract"},{"id":"mag:2407547357","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/3458430","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2019267045","https://openalex.org/W1965339325","https://openalex.org/W2414147608","https://openalex.org/W2415559001","https://openalex.org/W2321195922","https://openalex.org/W1908115926","https://openalex.org/W2413729765","https://openalex.org/W1999088650","https://openalex.org/W2348655764","https://openalex.org/W2007657013"],"abstract_inverted_index":{"The":[0,30,39,70,111,135],"plasma":[1],"levels":[2],"of":[3,16,23,73,85,105,113,126,141,149,153,156,164],"epirubicin":[4,17,142,157],"and":[5,27,44,51,64,130],"its":[6],"metabolite,":[7],"epirubicinol,":[8,114],"were":[9,46,56],"measured":[10],"by":[11,58,102],"HPLC":[12],"following":[13],"intravenous":[14],"administration":[15],"to":[18,108,146,159,162],"cancer":[19],"patients":[20],"at":[21],"doses":[22],"40,":[24],"60,":[25],"80,":[26],"100":[28],"mg/m2.":[29],"blood":[31],"concentration/time":[32],"curve":[33,139],"declined":[34],"as":[35],"a":[36,59,65,117,132],"tri-phasic":[37],"function.":[38],"mean":[40],"t1/2":[41],"alpha,":[42],"beta,":[43],"gamma":[45],"4.67":[47],"min,":[48],"1.15":[49],"h,":[50,53],"36.5":[52],"respectively,":[54],"which":[55,98],"characterized":[57],"short":[60],"distribution":[61,71],"phase":[62,68],"(alpha)":[63],"prolonged":[66],"elimination":[67],"(gamma).":[69],"volume":[72],"the":[74,86,103,106,127,138,147],"central":[75],"compartment":[76,88],"(V1":[77],"=":[78,90,93],"0.351":[79],"l/kg)":[80,95],"was":[81,96,122],"small,":[82],"while":[83],"that":[84,125],"tissue":[87],"(V2":[89],"0.254,":[91],"V3":[92],"45.8":[94],"large,":[97],"could":[99],"be":[100,160],"explained":[101],"binding":[104],"drug":[107,129],"cellular":[109],"components.":[110],"concentration":[112],"although":[115],"having":[116],"wide":[118],"variation":[119],"among":[120],"individuals,":[121],"less":[123],"than":[124],"unchanged":[128],"showed":[131],"gradual":[133],"decline.":[134],"area":[136],"under":[137],"(AUC)":[140],"increased":[143],"in":[144],"proportion":[145],"increase":[148],"dosage.":[150],"These":[151],"types":[152],"pharmacokinetic":[154],"behavior":[155],"appeared":[158],"similar":[161],"those":[163],"doxorubicin.":[165]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2016-06-24T00:00:00"}